Owlet, Inc. (OWLT)
USD 4.46
(-4.9%)
USD 4.46
(-4.9%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 54.01 Million USD | -21.95% |
| 2022 | 69.2 Million USD | -8.71% |
| 2021 | 75.8 Million USD | 0.53% |
| 2020 | 75.4 Million USD | 51.41% |
| 2019 | 49.8 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 20.69 Million USD | 40.33% |
| 2024 Q1 | 14.75 Million USD | -29.76% |
| 2023 Q3 | 9.18 Million USD | -29.84% |
| 2023 FY | 54.01 Million USD | -21.95% |
| 2023 Q4 | 21 Million USD | 128.71% |
| 2023 Q2 | 13.08 Million USD | 22.32% |
| 2023 Q1 | 10.7 Million USD | -10.83% |
| 2022 Q4 | 12 Million USD | -30.87% |
| 2022 Q3 | 17.35 Million USD | -5.14% |
| 2022 Q1 | 21.53 Million USD | 961.52% |
| 2022 FY | 69.2 Million USD | -8.71% |
| 2022 Q2 | 18.3 Million USD | -15.03% |
| 2021 Q1 | 21.91 Million USD | 4.35% |
| 2021 Q4 | -2.5 Million USD | -107.94% |
| 2021 Q3 | 31.5 Million USD | 26.33% |
| 2021 FY | 75.8 Million USD | 0.53% |
| 2021 Q2 | 24.93 Million USD | 13.81% |
| 2020 Q1 | 14.87 Million USD | 0.0% |
| 2020 Q4 | 20.99 Million USD | -0.81% |
| 2020 Q3 | 21.16 Million USD | 15.27% |
| 2020 Q2 | 18.36 Million USD | 23.5% |
| 2020 FY | 75.4 Million USD | 51.41% |
| 2019 FY | 49.8 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Abbott Laboratories | 40.1 Billion USD | 99.865% |
| Allurion Technologies Inc. | 53.46 Million USD | -1.016% |
| Artivion, Inc. | 354 Million USD | 84.743% |
| Avanos Medical, Inc. | 673.3 Million USD | 91.978% |
| Butterfly Network, Inc. | 65.9 Million USD | 18.042% |
| Butterfly Network, Inc. | 65.9 Million USD | 18.042% |
| Bio-Rad Laboratories, Inc. | 2.67 Billion USD | 97.978% |
| Boston Scientific Corporation | 14.24 Billion USD | 99.621% |
| Perspective Therapeutics, Inc. | 7.1 Million USD | -660.276% |
| CONMED Corporation | 1.24 Billion USD | 95.648% |
| Edwards Lifesciences Corporation | 6 Billion USD | 99.101% |
| Paragon 28, Inc. | 216.38 Million USD | 75.04% |
| Glaukos Corporation | 314.71 Million USD | 82.838% |
| Globus Medical, Inc. | 1.56 Billion USD | 96.557% |
| Inspire Medical Systems, Inc. | 624.79 Million USD | 91.356% |
| Integer Holdings Corporation | 1.59 Billion USD | 96.617% |
| Medtronic plc | 32.36 Billion USD | 99.833% |
| Nevro Corp. | 425.17 Million USD | 87.297% |
| Penumbra, Inc. | 1.05 Billion USD | 94.898% |
| Vicarious Surgical Inc. | - USD | -Infinity% |
| Smith & Nephew plc | 5.54 Billion USD | 99.027% |
| Sonendo, Inc. | 43.86 Million USD | -23.128% |
| STERIS plc | 5.13 Billion USD | 98.949% |
| Stryker Corporation | 20.49 Billion USD | 99.737% |
| Vapotherm, Inc. | 68.66 Million USD | 21.347% |
| Zimmer Biomet Holdings, Inc. | 7.39 Billion USD | 99.27% |